Board of Directors

Marc Rubin, M.D., has served on the Board since June 2010. Dr. Rubin was President and Chief Executive Officer of Titan Pharmaceuticals from October 2007 to December 2008, Executive Chairman of the Board of Directors from May 2009 to August 2022, and a member of the Board from August 2022 to September 2023. From June 2006 until February 2007, he served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Beginning in October 2003 and until the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG with responsibility for global development and for three global business units, including the oncology business unit, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, he held positions in global clinical and commercial development at GlaxoSmithKline, where he oversaw programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, Dr. Rubin was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. He holds an M.D. from Cornell University Medical College.

Committee:

Audit
Compensation